CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Polaris Group is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Polaris Group
Ugland House
P.O. Box 309
GRAND CAYMAN, KY1-1104  Cayman Islands Ticker: 65506550
Business Summary
Polaris Group is a Cayman Islands-based biopharmaceutical company, which is engaged in advanced therapies, primarily focusing on metabolic related diseases. The Company’s drug candidate, Pegargiminase (ADI-PEG 20), is advancing through the biologics license applications (BLA) - enabling stage and clinical development. Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Pegargiminase is designed to disrupt cancer cell metabolism, providing a novel approach to treating a range of cancers heavily influenced by metabolic pathways. The Company’s product pipeline also includes peptide drugs, such as the Semaglutide-related products.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Hong-WenChen 12/21/2023 11/24/2014
Chief Executive Officer, Director ZhanpingXu 1/2/2024 12/21/2023
General Manager-Clinical Affairs AmandaJohnston 10/1/2010 10/1/2010
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Polaris Pharmaceuticals, Inc. 10675 Sorrento Valley Road San Diego CA United States

Business Names
Business Name
6550
DesigneRx Pharmaceuticals, Inc.
Polaris Pharmaceuticals, Inc.
TDW Pharmaceuticals, Inc.

General Information
Outstanding Shares: 744,420,732 (As of 3/31/2024)
Shareholders: 31,238
Stock Exchange: TPE


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024